Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00161733 · ClinicalTrials.gov registry record · Phase 3
Safety and Hemostatic Efficacy of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated (FS VH S/D) Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery
A Phase 3 study of Cardiopulmonary Bypass and Sternotomy, sponsored by Baxter Healthcare Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
NCT00161733 is a Phase 3 study of Cardiopulmonary Bypass and Sternotomy that has completed, run by Baxter Healthcare Corporation. The trial reports 20 study locations across 16 states.
The verdict
NCT00161733, a Phase 3 study of Cardiopulmonary Bypass and Sternotomy, has completed, sponsored by Baxter Healthcare Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
Study Summary
The objective of this study is to demonstrate equivalent hemostatic efficacy and safety between FS VH S/D and TISSEEL VH fibrin sealant in subjects undergoing cardiac surgery requiring cardiopulmonary bypass. If bleeding is still present after conventional surgical methods to achieve hemostasis have been applied FS VH S/D or Tisseel VH are applied. Achievement of hemostasis within 5 minutes is compared between the study groups.
Conditions Studied
Interventions
- DRUG Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D)
- DRUG TISSEEL VH fibrin sealant
Study Locations (20)
Florida
- Shands Hospital at the University of Florida - Gainesville
- Brevard Cardio Surgeons/Health First Heart Institute - Melbourne
Georgia
- Peachtree Cardiovascular - Atlanta
- St. Joseph's/Candler Health System, Inc. - Savannah
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Cardiac Surgery Service, Baystate Medical Center - Springfield
Ohio
- The Linder Clinical Trial Center - Cincinnati
- The Cleveland Clinic - Cleveland
Arizona
- Banner Health Research Institute - Phoenix
California
- UCI Medical Center - Orange
Illinois
- University of Chicago Medical Center - Chicago
Kentucky
- University of Kentucky Medical Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-09 |
| Est. Completion | 2004-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00161733
The ClinicalTrials.gov registry entry for NCT00161733 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Baxter Healthcare Corporation, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cardiopulmonary Bypass appearing as the primary indexed condition, and to 2 interventions - of which Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D) is the first listed.
NCT00161733 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00161733 about?
NCT00161733 is a clinical study titled "Safety and Hemostatic Efficacy of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated (FS VH S/D) Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery". The objective of this study is to demonstrate equivalent hemostatic efficacy and safety between FS VH S/D and TISSEEL VH fibrin sealant in subjects undergoing cardiac surgery requiring cardiopulmonary bypass. If bleeding is still present after conventional surgical methods to achieve hemostasis have...
What is the current status of trial NCT00161733?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-09. Estimated completion is 2004-11.
What conditions does trial NCT00161733 study?
This clinical trial studies the following conditions: Cardiopulmonary Bypass, Sternotomy, Cardiac Surgery Requiring Cardiopulmonary Bypass and Median Sternotomy.
What interventions are being tested in trial NCT00161733?
The interventions under investigation include: Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D) (DRUG), TISSEEL VH fibrin sealant (DRUG).
Who is sponsoring clinical trial NCT00161733?
This trial is sponsored by Baxter Healthcare Corporation, which has 46 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00161733 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiopulmonary Bypass
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
RECRUITING · Phase 3
-
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
ACTIVE NOT RECRUITING · Phase 3
-
Neutrophil Phenotypic Profiling and Acute Lung Injury in Patients After Cardiopulmonary Bypass (CPB)
RECRUITING
-
Cardiopulmonary Bypass Induced Red Blood Cell Lysis
RECRUITING
-
SPY Imaging System: Its Role in Pediatric Cardiac Surgery
COMPLETED
-
Acetaminophen for Oxidative Stress After Cardiopulmonary Bypass
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.